scispace - formally typeset
V

Vladimir Korinek

Researcher at Academy of Sciences of the Czech Republic

Publications -  75
Citations -  15445

Vladimir Korinek is an academic researcher from Academy of Sciences of the Czech Republic. The author has contributed to research in topics: Wnt signaling pathway & Beta-catenin. The author has an hindex of 28, co-authored 66 publications receiving 14542 citations. Previous affiliations of Vladimir Korinek include Utrecht University & Johns Hopkins University.

Papers
More filters
Journal ArticleDOI

Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

TL;DR: Results indicate that regulation of β-catenin is critical to APC's tumor suppressive effect and that this regulation can be circumvented by mutations in either APC or β- catenin.
Journal ArticleDOI

Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma

TL;DR: Constitutive transcription of Tcf target genes, caused by loss of APC function, may be a crucial event in the early transformation of colonic epithelium.
Journal ArticleDOI

XTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos

TL;DR: It is proposed that signaling by beta-catenin involves complex formation with XT cf-3, followed by nuclear translocation and activation of specific XTcf-3 target genes, which suppresses endogenous axis specification upon injection into the dorsal blastomeres of a 4-cell-stage embryo.
Journal ArticleDOI

Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4.

TL;DR: The role of Tcf-4 in colon cancer was investigated in this paper, where the authors found that Tcf7/2//- mice die shortly after birth from colon cancer.
Journal ArticleDOI

Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway

TL;DR: In this paper, the authors analyzed CD44 expression in the intestinal mucosa of mice and humans with genetic defects in either APC or Tcf-4, leading to constitutive activation or blockade of the β-catenin/Tcf4 pathway, respectively.